Comments

Emergent BioSolutions Analyst Ratings

EBSNYSE

Logo brought to you by Benzinga Data

Trade with Public

$12.33

0.928.06%

At close: Dec 12, 4:00 PM EST

$12.36

0.030.24%

Pre-Market: 8:55 AM EST

Overview News Earnings Options Guidance

Analyst Ratings

Insider Trades Short Interest Government Trades Stock Report

Consensus Rating¹

Buy

Highest Price Target¹

$16.00

Lowest Price Target¹

$12.00

Consensus Price Target¹

$14.75

Emergent BioSolutions Analyst Ratings and Price Targets | NYSE:EBS | Benzinga

Emergent BioSolutions Inc has a consensus price target of $14.75 based on the ratings of 5 analysts. The high is $16 issued by Rodman & Renshaw on September 13, 2024. The low is $12 issued by Benchmark on November 7, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on December 16, 2025, September 3, 2025, and April 1, 2025, respectively. With an average price target of $15 between HC Wainwright & Co., there's an implied 21.36% upside for Emergent BioSolutions Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Sep

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

HC Wainwright & Co.

Benchmark

Rodman & Renshaw

¹calculated from analyst ratings

Analyst Ratings for Emergent BioSolutions

					Get Alert
Dec 16, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Sep 3, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Apr 1, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Mar 21, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Mar 4, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Jan 21, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Jan 10, 2025	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15 15	Previous Buy Current Buy	Get Alert
Dec 30, 2024	21.36%	Raghuram SelvarajuHC Wainwright & Co. 65%	15	Previous Initiates Current Buy	Get Alert
Nov 7, 2024	-2.91%	Robert WassermanBenchmark 57%	8 12	Previous Buy Current Buy	Get Alert
Sep 13, 2024	29.45%	Brandon FolkesRodman & Renshaw 59%	16 16	Previous Buy Current Buy	Get Alert
Aug 22, 2024	29.45%	—	16	Previous Initiates Current Buy	Get Alert
Aug 16, 2024	-35.28%	Robert WassermanBenchmark 57%	8 8	Previous Buy Current Buy	Get Alert
Aug 9, 2024	-35.28%	Robert WassermanBenchmark 57%	8 8	Previous Buy Current Buy	Get Alert
Jul 3, 2024	-35.28%	Robert WassermanBenchmark 57%	8 8	Previous Buy Current Buy	Get Alert
Jul 2, 2024	-35.28%	Robert WassermanBenchmark 57%	8 8	Previous Buy Current Buy	Get Alert
Jun 24, 2024	-35.28%	Robert WassermanBenchmark 57%	8 8	Previous Buy Current Buy	Get Alert
Jun 21, 2024	-35.28%	Robert WassermanBenchmark 57%	8 8	Previous Buy Current Buy	Get Alert
Jun 20, 2024	-35.28%	Robert WassermanBenchmark 57%	5 8	Previous Buy Current Buy	Get Alert
Apr 11, 2024	-59.55%	Robert WassermanBenchmark 57%	5 5	Previous Buy Current Buy	Get Alert
Mar 7, 2024	-59.55%	Robert WassermanBenchmark 57%	5	Previous Hold Current Buy	Get Alert
Nov 20, 2023	—	Jessica FyeJP Morgan 72%	—	Previous Current Underweight	Get Alert
Aug 29, 2023	—	Robert WassermanBenchmark 57%	—	Previous Buy Current Hold	Get Alert
May 31, 2023	77.99%	Robert WassermanBenchmark 57%	22	Previous Buy Current Buy	Get Alert
May 19, 2023	77.99%	Robert WassermanBenchmark 57%	22	Previous Buy Current Buy	Get Alert
Apr 10, 2023	77.99%	Robert WassermanBenchmark 57%	22	Previous Hold Current Buy	Get Alert
Mar 17, 2023	-27.18%	Jessica FyeJP Morgan 72%	9 23	Previous Neutral Current Underweight	Get Alert

FAQ

What is the target price for Emergent BioSolutions (EBS) stock?

The latest price target for Emergent BioSolutions (NYSE:EBS) was reported by HC Wainwright & Co. on December 16, 2025. The analyst firm set a price target for $15.00 expecting EBS to rise to within 12 months (a possible 21.36% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Emergent BioSolutions (EBS)?

The latest analyst rating for Emergent BioSolutions (NYSE:EBS) was provided by HC Wainwright & Co., and Emergent BioSolutions reiterated their buy rating.

When was the last upgrade for Emergent BioSolutions (EBS)?

The last upgrade for Emergent BioSolutions Inc happened on March 7, 2024 when Benchmark raised their price target to $5. Benchmark previously had a hold for Emergent BioSolutions Inc.

When was the last downgrade for Emergent BioSolutions (EBS)?

The last downgrade for Emergent BioSolutions Inc happened on August 29, 2023 when Benchmark changed their price target from N/A to N/A for Emergent BioSolutions Inc.

When is the next analyst rating going to be posted or updated for Emergent BioSolutions (EBS)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Emergent BioSolutions, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Emergent BioSolutions was filed on December 16, 2025 so you should expect the next rating to be made available sometime around December 16, 2026.

Is the Analyst Rating Emergent BioSolutions (EBS) correct?

While ratings are subjective and will change, the latest Emergent BioSolutions (EBS) rating was a reiterated with a price target of $15.00 to $15.00. The current price Emergent BioSolutions (EBS) is trading at is $12.36, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.